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Hepatocellular  carcinoma  (HCC)  is  the  third  leading  cause  of 
cancer-induced death worldwide, and patients have a very poor 
prognosis (1–3). Surgical resection, in the form of partial hepatec-
tomy or liver transplantation, is the mainstay of curative treatment. 
Nonetheless, recurrence of HCC is still common after curative 
surgery. In addition, HCC is frequently diagnosed at an advanced 
stage and thus precludes curative treatment. No effective thera-
peutic option exists for the treatment of the majority of patients 
with liver cancer (4–8). Etiologically, HCC commonly occurs in 
patients  with  chronic  hepatitis,  resulting  from  inflammation  in 
response to hepatitis B virus (HBV) or hepatitis C virus (HCV) 
infections. In fact, more than half of all HCCs in the world are 
attributed to chronic hepatitis B (1–3,9). Although this link has 
been recognized for decades, the molecular mechanisms of how 
chronic  hepatitis  promotes  HCC  tumorigenesis  and  metastasis 
remain largely unclear.
The epithelial–mesenchymal transition (EMT), in which epi-
thelial cancer cells lose their polarity and become motile mesen-
chymal cells, has been implicated in cancer invasion and metastasis 
(10). Cancer cells undergoing EMT appear to exhibit properties of 
cancer  stem  cells  (11),  override  oncogene-induced  premature 
senescence and apoptosis (12), and contribute to immunosuppression 
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  Background  Expression of the polymeric immunoglobulin receptor (pIgR), a transporter of polymeric IgA and IgM, is com-
monly increased in response to viral or bacterial infections, linking innate and adaptive immunity. Abnormal 
expression of pIgR in cancer was also observed, but its clinical relevance remains uncertain.
  Methods  A human hepatocellular carcinoma (HCC) tissue microarray (n = 254) was used to investigate the association 
between pIgR expression and early recurrence. An experimental lung metastasis model using severe combined 
immune-deficient mice was applied to determine the metastatic potential of Madin–Darby canine kidney (n = 5 mice 
per group) and SMMC-7721 (n = 12 mice per group) cells overexpressing pIgR vs control cells. RNA interference, 
immunoprecipitation, and immunoblotting were performed to investigate the potential role for pIgR in the induc-
tion of epithelial–mesenchymal transition (EMT). In vitro studies (co-immunoprecipitation, immunoblotting, and   
migration,  invasion,  and  adhesion  assays)  were  used  to  determine  the  mechanisms  behind  pIgR-mediated 
metastasis. All statistical tests were two-sided.
  Results  High expression of pIgR was statistically significantly associated with early recurrence in early-stage HCC and 
in hepatitis B surface antigen–positive HCC patients (log-rank P = .02). Mice injected with pIgR-overexpressing 
cells had a statistically significantly higher number of lung metastases compared with respective control cells 
(Madin–Darby canine kidney cells: pIgR mean = 29.4 metastatic nodules per lung vs control mean = 0.0 meta-
static nodules per lung, difference = 29.4 metastatic nodules per lung, 95% confidence interval = 13.0 to 45.8,   
P = .001; SMMC-7721 cells: pIgR mean = 10.4 metastatic nodules per lung vs control mean = 2.2 metastatic 
nodules per lung, difference = 8.2 metastatic nodules per lung, 95% confidence interval = 1.0 to 15.5, P = .03). 
Furthermore, high expression of pIgR was sufficient to induce EMT through activation of Smad signaling.
  Conclusions  pIgR plays a role in the induction of EMT. Our results identify pIgR as a potential link between hepatitis B virus–
derived hepatitis and HCC metastasis and provide evidence in support of pIgR as a prognostic biomarker for 
HCC and a potential therapeutic target.
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(13), indicating the vital role of EMT in tumor recurrence. Recent 
advances in understanding cancer progression point to EMT as a 
key  event  linking  inflammation  with  cancer  metastasis  (14).  As 
EMT appears to play a pivotal role in hepatocellular dissemination 
during HCC progression (15), probing insights into the molecular 
mechanisms of how EMT links chronic hepatitis and HCC pro-
gression may benefit the pathological assessments and therapeutic 
options for these patients.
The  polymeric  immunoglobulin  receptor  (pIgR)  is  a  trans-
porter of dimeric IgA (dIgA) and pentameric IgM (pIgM), which 
are the first-line antibodies in response to initial infection. Widely 
expressed  in  epithelial  cells,  pIgR  expression  is  also  commonly 
increased  by  proinflammatory  cytokines  in  response  to  viral  or 
bacterial  infections,  thus  linking  innate  and  adaptive  immunity 
(16–19). Abnormal expression of pIgR in malignantly transformed 
epithelial cells was initially reported 30 years ago (20–23). High 
levels of the cleaved extracellular domain of pIgR, designated as 
the secretory component, were also detected in the sera of patients 
with  HCC  and  colonic  carcinoma  with  liver  metastasis  (24). 
However, the clinical relevance and potential function of pIgR in 
tumor cells remain uncertain.
In this study, we investigated the relationship between pIgR 
expression and clinical outcome (overall survival, recurrence and 
disease-free survival [DFS]) in 254 HCC patients enrolled in a 
Chinese study. The potential role for pIgR in EMT was investi-
gated  in  patient  samples  and  HCC  cell  lines  by  immunohisto-
chemistry (IHC), co-immunoprecipitation, immunoblotting, and 
migration, invasion, and adhesion assays. Furthermore, we studied 
the metastatic potential of pIgR-overexpressing cells in an experi-
mental lung metastasis mouse model.
Materials and Methods
Clinical Specimens and Analysis of pIgR Expression
Tumor  specimens  were  randomly  collected  from  254  HCC 
patients  during  curative  resection  from  February  15,  2004,  to 
December 15, 2005, in the Liver Cancer Institute, Zhong Shan 
Hospital, Shanghai, China. The entrance criteria and postsurgical 
patient  surveillance  were  similar  to  those  specified  in  previous 
reports (25,26). Briefly, the enrollment criteria for all patients in 
this study were 1) definitive HCC diagnosis by pathology on the 
basis of the World Health Organization criteria; 2) no prior anti-
cancer treatment; 3) surgical resection, defined as complete resec-
tion of all tumor nodules with the cut surface being free of cancer 
by  histological  examination;  4)  availability  of  suitable  formalin-
fixed paraffin-embedded tissues and frozen tissues; and 5) avail-
ability of complete clinicopathologic and follow-up data. Tumor 
differentiation was defined according to the Edmondson grading 
system  (27),  and  liver  function  was  assessed  by  Child–Pugh 
classification (28). Tumor staging was defined according to the 
Sixth  Edition  of  American  Joint  Committee  on  Cancer  TNM 
staging manual (29). Patients were re-assessed every 2 months in 
the first postoperative year and at least every 3–4 months after-
ward. Follow-up was terminated on May 3, 2010. Most patients 
died of intrahepatic recurrence, distal metastasis, or complicated 
liver cirrhosis. All patients were monitored prospectively by serum 
a-fetoprotein measurement, abdomen ultrasonography, and chest 
x-ray every 1–6 months, according to the postoperative time. For 
patients  with  test  results  suggestive  of  recurrence,  computed 
tomography  and/or  magnetic  resonance  imaging  were  used  to 
verify whether intrahepatic recurrence and/or distal metastasis had 
occurred. The diagnosis of recurrence was made on the basis of 
typical imaging appearance in computed tomography and/or mag-
netic resonance imaging scan and an elevated a-fetoprotein level. 
Patients with confirmed recurrence received further treatments, 
which followed the same protocol on the basis of tumor size, site, 
number of tumor nodules, and liver function. Briefly, if the recur-
rent tumor was localized, a second liver resection, radiofrequency 
ablation, or percutaneous ethanol injection was suggested. If the 
recurrent  tumor  was  multiple  or  diffused,  transcatheter  arterial 
chemoembolization was recommended. External radiotherapy was 
given if lymph node or bone metastases were found; otherwise, 
symptomatic treatment was provided.
Overall survival was defined as the interval between surgery and 
either death or the last observation taken. Data were censored at 
the last follow-up period for living patients. DFS was measured 
from the date of resection until either detection of recurrent tumor 
or the last follow-up assessment. In the DFS analysis, data were 
CONTEXT AND CAVEATS
Prior knowledge
Although hepatocellular carcinoma (HCC) has been linked to chronic 
hepatitis B, the underlying molecular mechanisms behind tumori-
genesis and metastasis in chronic hepatitis B patients are unclear.
Study design
The polymeric immunoglobulin receptor (pIgR) transports immu-
noglobulins, and its expression is increased in response to proin-
flammatory cytokines as part of the adaptive immune response. 
Abnormal expression of pIgR has been previously reported in HCC 
patients.  This  study  investigated  the  relationship  between  pIgR 
expression and clinical outcome in 254 HCC patients. In vitro and 
in vivo experiments with human HCC cell lines were done to deter-
mine the role of pIgR in epithelial–mesenchymal transition.
Contribution
High expression of pIgR was associated with early recurrence in 
patients with early-stage disease and in those who were positive 
for hepatitis B. Overexpression of pIgR resulted in increased lung 
metastases  in  an  experimental  lung  metastases  model.  In  vitro 
experiments show that overexpression of pIgR induces epithelial–
mesenchymal transition in HCC cells, which is regulated through 
the activation of Smad signaling.
Implications
pIgR-mediated  epithelial–mesenchymal  transition  is  a  potential 
underlying biological mechanism behind the development of HCC 
and metastases in chronic hepatitis B patients. pIgR may also be a 
prognostic biomarker and potential therapeutic target for HCC.
Limitations
The pathway involved in the development and progression of HCC 
in hepatitis B patients may be more complex and include multiple 
converging  pathways  that  regulate  epithelial–mesenchymal 
transition.  Further  studies  to  determine  the  cause  of  abnormal 
pIgR expression and potential therapeutic strategies are needed.
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censored  for  patients  without  tumor  recurrence,  which  repre-
sented the occurrence of metastases or de novo tumors and were 
grouped as early (≤2 years) or late (>2 years) recurrence (30–33). 
For patients who had a confirmed tumor recurrence, DFS was 
calculated  as  the  time  that  early  recurrence  was  first  suspected 
(34,35).  Kaplan–Meier  survival  analysis  of  male  and  female 
patients  with  high  or  low  pIgR  expression  was  performed,  and   
P values were calculated using a two-sided log-rank test. Ethical 
approval  for  the  use  of  human  subjects  was  obtained  from  the 
Research Ethics Committee of Zhong Shan Hospital. All patients 
provided written informed consent.
Expression of pIgR and E-cadherin was analyzed via IHC using 
tissue microarrays, which were constructed as described previously 
(25,26). Briefly, two core biopsies 1 mm in diameter were obtained 
from the donor blocks and transferred to the recipient paraffin 
block at defined array positions. Four different tissue microarray 
blocks,  including  tumor  and  peritumor  tissue  specimens,  were 
constructed. IHC for pIgR and E-cadherin was performed with 
monoclonal rabbit anti-human pIgR antibody (dilution, 1:100) or 
monoclonal  mouse  anti-human  E-cadherin  antibody  (dilution, 
1:600) following a two-step protocol (Novolink Polymer Detection 
System; Novocastra, Newcastle, UK). IHC staining was assessed 
by  two  independent  pathologists  with  no  prior  knowledge  of 
patient  characteristics  (Bo  Yang  and  Yuan  Ji,  Department  of 
Pathology,  Zhongshan  Hospital,  Fudan  University,  Shanghai, 
China). Discrepancies were resolved by consensus. The staining 
extent score was on a scale of 0–4, corresponding to the percentage 
of immunoreactive tumor cells (0%, 1%–5%, 6%–25%, 26%–75%, 
and 76%–100%, respectively). The staining intensity was scored as 
negative (score = 0), weak (score = 1), or strong (score = 2). A score 
ranging from 0–8 was calculated by multiplying the staining extent 
score with the intensity score, resulting in a low (0–4) or a high 
(6–8) expression value for each specimen (36).
Cell Culture
The Madin–Darby canine kidney (MDCK) and human colon ade-
nocarcinoma HT29 cell lines were purchased from the American 
Type Culture Collection (Manassas, VA). The hepatic carcinoma 
cell  line  SMMC-7721  was  obtained  from  the  Institute  of 
Biochemistry  and  Cell  Biology,  Chinese  Academy  of  Sciences 
(Shanghai, China). Cells were cultured according to the suppliers’ 
instructions. Briefly, MDCK cells were grown in Delbecco’s mod-
ified  Eagle  medium  (DMEM;  Invitrogen,  Grand  Island,  NY) 
supplemented  with  10%  fetal  bovine  serum  (FBS;  Invitrogen). 
HT29  cells  were  grown  in  McCoy’s  5A  medium  (Invitrogen) 
supplemented with 10% FBS. SMMC-7721 cells was cultured in 
RPMI-1640 medium (Invitrogen) supplemented with 10% FBS 
(Hangzhou  Sijiqing  Biological  Engineering  Materials  Co,  Ltd, 
Hangzhou,  China).  The  Phoenix  Retroviral  Expression  System 
was obtained from American Type Culture Collection (distributed 
by LGC standards, Middlesex, UK) and grown in DMEM supple-
mented with 10% FBS. All cell lines were authenticated by using 
short tandem repeat analysis in July 2009.
Monoclonal and Polyclonal Antibodies
The monoclonal mouse anti-human E-cadherin antibody and the 
monoclonal  mouse  anti-human  EEA1  antibody  were  purchased 
from BD Biosciences (San Diego, CA). The monoclonal rabbit 
anti-human  Smad2  antibody,  the  polyclonal  rabbit  anti-human 
phospho-Smad2  (Ser465/467)  antibody,  the  monoclonal  rabbit 
anti-human Smad3 antibody, the monoclonal rabbit anti-human 
phospho-Smad3  (Ser423/425)  antibody,  the  monoclonal  mouse 
anti-human Snail antibody, and the monoclonal mouse anti-human 
Slug antibody were purchased from Cell Signaling Technology 
(Danvers,  MA).  The  monoclonal  mouse  anti-human  vimentin 
antibody and the monoclonal mouse anti-human fibronectin anti-
body were purchased from Abcam (Cambridge, UK). The poly-
clonal rabbit anti-human pIgR (H300), polyclonal goat anti-human 
pIgR (N16), polyclonal goat anti-human pIgR (C20), polyclonal 
rabbit anti-Smad4, normal rabbit IgG, and normal goat IgG anti-
bodies  were  purchased  from  Santa  Cruz  Biotechnology  (Santa 
Cruz, CA). The monoclonal mouse anti-human pan-cytokeratin 
antibody, polyclonal rabbit anti-human b-actin antibody, mono-
clonal mouse anti-human TWIST1 antibody, monoclonal mouse 
anti-human TWIST2 antibody, and polyclonal rabbit anti-human 
ZEB1 antibody were purchased from Sigma-Aldrich (St Louis, MO). 
The monoclonal mouse anti-human glyceraldehyde-3-phosphate 
dehydrogenase  (GAPDH)  antibody,  horseradish  peroxidase–
conjugated anti-mouse, anti-goat, and anti-rabbit secondary anti-
bodies were all purchased from KangChen Bio-tech (Shanghai, 
China). Alexa Fluor 488 goat anti-rabbit IgG, Alexa Fluor 488 
rabbit anti-mouse IgG, Alexa Flour 488 rabbit anti-goat IgG, 
and Alexa Flour 488 goat anti-rabbit IgG were purchased from 
Invitrogen.
Plasmids
Human pIgR cDNA-containing pcDNA3.1 (+) was a generous gift 
from Dr Finn-Eirik Johansen (Rikshospitalet University Hospital, 
Oslo, Norway). The template sequences for pIgR short hairpin 
RNA (shRNA) were obtained using the Insert Design Tool for the 
pSilencer  Vector  of  Ambion  (Austin,  TX).  The  template  pIgR 
shRNA and non-silencing shRNA were chemically synthesized by 
GenePharma Co (Shanghai, China), annealed to form duplexes 
(90°C for 3 minutes followed by an incubation at 37°C for 1 hour), 
and subcloned into pSilencer2.1/Puro vector (Ambion) with T4 DNA 
ligase at 14°C for 16 hours. Human pIgR mutants were generated 
using the Muta-direct Site-directed Mutagenesis kit (Beijing SBS 
Genetech Co, Ltd, Beijing, China). pBABE-puro-pIgR plasmids 
were  constructed  using  recombinant  polymerase  chain  reaction 
and subsequently were subcloned into the vectors. The polymerase 
chain  reaction  conditions  were  as  follows:  94°C  for  5  minutes;   
30 cycles of 94°C for 1 minute, 60°C for 1 minute, and 72°C for 
2.5 minutes; 72°C for 10 minutes. The polymerase chain reaction 
product was cloned into pBABE-puro vector at the EcoRI restric-
tion site. All constructs were sequenced by Invitrogen.
Transfection and Infection
For stable transfections, MDCK cells were grown to 60% conflu-
ency  in  six-well  plates  and  transfected  with  4  µg  of  full-length 
pcDNA3.1  (+)  vector  or  pcDNA3.1  (+)-pIgR,  using  10  µL  of 
Lipofectamine  2000  (Invitrogen)  following  the  manufacturer’s   
instructions. A monoclonal population of stably transfected cells 
was  selected  using  800  µg/mL  geneticin  (G418)  (Invitrogen). 
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plates and transfected with 4 µg full-length pSilencer2.1/Puro-con 
shRNA vector or the indicated pSilencer2.1/Puro-shRNA, using 
10  µL  of  Lipofectamine  2000  following  the  manufacturer’s   
instructions. A monoclonal population of stably transfected cells 
was  selected  using  2  µg/mL  puromycin  (Invitrogen).  Transient 
transfection in MDCK and SMMC-7721 cells were performed as 
described  above  except  that  cells  were  directly  harvested  for 
analysis 48 hours after transfection.
For infection, phoenix cells (American Type Culture Collection) 
were grown in DMEM supplemented with 10% FBS to 60% con-
fluency in 10-cm dishes and transfected with 24 µg of the retroviral 
constructs (described above) in antibiotic-free DMEM containing 
10% FBS using 60 µL of Lipofectamine 2000 according to the 
manufacturer’s instructions. Approximately 24 hours after trans-
fection, the media was changed to fresh DMEM containing 10% 
FBS. After an additional 24-hour incubation at 37°C, the supernatant 
was  collected,  filtered  using  a  0.45-µm  filter  (Millipore,  Cork, 
Ireland), and used to infect SMMC-7721 cells in the presence of   
4 µg/mL polybrene (Millipore). Polyclonal populations of infected 
cells were then selected using 1 µg/mL puromycin.
RNA Interference
pIgR shRNAs were synthesized and cloned into a pSilencer2.1/
Puro vector (Ambion). Target sequences for the shRNAs were as 
follows:  pIgR  shRNA1,  5′-GAACGUCGACCGAGUUUCA-3′; 
pIgR  shRNA2,  5′-CGUCGACCGAGUUUCAAUC-3′;  and 
pIgR shRNA3, 5′-GAAGAGUUUGUUGCCACCA-3′. Shanghai 
GenePharm (Shanghai, China) synthesized short interfering RNA 
(siRNAs) sequences specifically targeting human pIgR (5′-GAA
GAGUUUGUUGCCACCATT-3′),  human  Smad2  (5′-GGU
GUUCGAUAGCAUAUUATT-3′), human Smad3 (5′-GCCU
GGUCAAGAAACUCAATT-3′), canine Smad2 (5′-ACAUAUA
GGAAGAGGAGUATT-3′), canine Smad3 (5′-GAGGAGAAGU
GGUGCGAGATT-3′),  and  non-targeting  control  siRNA 
(5′-UUCUC  CGAACGUGUCACGUTT-3′).  For  siRNA  delivery, 
double-stranded  RNA  oligonucleotides  were  transfected  using 
Oligofectamine  (Invitrogen).  MDCK,  HT29,  or  SMMC-7721 
cells at 30%–50% confluency in six-well plates were transfected 
with 100 nM siRNAs, using 3 µL of Oligofectamine according to 
the manufacturer’s instructions and harvested 48 hours after trans-
fection for analysis.
Co-Immunoprecipitation and Immunoblot Analysis
For total protein extraction, the indicated cell lines were grown in 
six-well plates or 10-cm dishes; were lysed in buffer consisting of 
25 mM HEPES (pH 7.5), 150 mM NaCl, 10 mM MgCl2·6H2O, 
0.1 mM EDTA, 1 mM sodium orthovanadate, 1% Nonidet P-40; 
and  supplemented  with  a  protease  inhibitor  cocktail  (Roche, 
Indianapolis,  IN)  and  then  centrifuged  at  12 000g  at  4°C  for 
15 minutes. The supernatants containing the cellular proteins were 
then collected, and the protein concentration was measured using 
Bicinchoninic Acid Protein Assay Reagent (Pierce, Rockford, IL).
For co-immunoprecipitation, the protein lysates (1 mg) were 
incubated with the appropriate antibodies with rocking for 4 hours 
at 4°C, followed by the incubation of protein A/G plus Agarose 
(Santa Cruz Biotechnology) for 6 hours to overnight at 4°C with 
rocking.  The  beads  were  then  washed  with  cold  lysis  buffer   
followed by centrifugation at 3000g at 4°C for 5 minutes. The 
bound proteins were then eluted using 0.2% sodium dodecyl sulfate.
Both  total  protein  lysates  and  eluted  proteins  from  the   
co-immunoprecipitation  experiment  were  separated  by  sodium 
dodecyl sulfate polyacrylamide gel electrophoresis and transferred 
to Hybond C Extra nitrocellulose membranes (GE Healthcare, 
Chalfont, St Giles, UK). Membranes were incubated in blocking 
solution containing 5% dry milk or 1% bovine serum albumin for 
1 hour at room temperature. The membranes were incubated at 
4°C  overnight  with  the  appropriate  primary  antibodies  (mouse 
anti-human  E-cadherin  antibody  [dilution,  1:5000],  rabbit  anti-
human  Smad2  antibody  [dilution,  1:1000],  rabbit  anti-human 
phospho-Smad2 [Ser465/467] antibody [dilution, 1:1000], rabbit 
anti-human Smad3 antibody [dilution, 1:1000], rabbit anti-human 
phospho-Smad3 [Ser423/425] antibody [dilution, 1:1000], mouse 
anti-human Snail antibody [dilution, 1:1000], mouse anti-human 
Slug antibody [dilution, 1:1000], mouse anti-human vimentin anti-
body [dilution, 1:2000], mouse anti-human fibronectin antibody 
[dilution, 1:1000], rabbit anti-human pIgR [H300] antibody [dilution, 
1:1000], goat anti-human pIgR [N16] antibody [dilution, 1:1000], 
goat anti-human pIgR [C20] antibody [dilution, 1:1000], rabbit 
anti-Smad4 antibody [dilution, 1:1000], mouse anti-human pan- 
cytokeratin  antibody  [dilution,  1:100 000],  rabbit  anti-human 
b-actin  antibody  [dilution,  1:100 000],  mouse  anti-human 
TWIST1 antibody [dilution, 1:1000], mouse anti-human TWIST2 
antibody  [dilution,  1:1000],  rabbit  anti-human  ZEB1  antibody 
[dilution,  1:1000],  or  mouse  anti-human  GAPDH  antibody 
[dilution, 1:5000]). The membranes were washed for 15 minutes 
with Tris-buffered saline containing Tween 20 (TBST) (25 mM 
Tris, 150 mM NaCl, 2 mM KCl, pH 7.4, supplemented with 0.1% 
Tween 20) three times, before incubation at room temperature for 
1  hour  with  horseradish  peroxidase–conjugated  anti-goat  IgG   
(dilution, 1:2000), anti-rabbit IgG (dilution, 1:2000), or anti-mouse 
IgG  (dilution,  1:2000)  antibody.  After  washing  the  membranes 
with TBST three times for 15 minutes, bound antibodies were 
visualized using Western Blotting Luminal Reagent (Pierce) and 
subsequent  exposure  to  KODAK  X-OMAT  BT  Film  (Kodak, 
Rochester, NY) for 30 seconds to 30 minutes. Immunoblotting   
for GAPDH or b-actin served as a protein loading control. All 
experiments were performed at least three independent times.
Experimental Lung Metastasis Model
Female severe combined immunodeficient (SCID) mice 6 weeks of 
age  were  supplied  by  the  Shanghai  Laboratory  Animal  Center, 
Chinese Academy of Sciences (Shanghai, China). Mice were housed 
five or six mice per cage in a specific pathogen-free room with a 
12-hour light/dark schedule at 25°C ± 1°C and were fed an autoclaved 
chow  diet  and  water  ad  libitum.  All  experiments  were  performed 
according to the institutional ethical guidelines on animal care and 
approved  by  the  Institute  Animal  Care  and  Use  Committee  at 
Shanghai  Institute  of  Materia  Medica.  The  mice  were  randomly   
divided into indicated groups before the injection, and the double-
blinded evaluation was performed when counting metastatic nodules.
The  metastatic  ability  of  pIgR-overexpressing  MDCK  and 
SMMC-7721  cells  and  respective  control  cells  was  determined 
following cell injection intravenously into the tail vein. MDCK 
cells (MDCK-mock, MDCK-pIgR, MDCK-pIgR-con.shRNA, or 1700   Articles | JNCI  Vol. 103, Issue 22  |  November 16, 2011
MDCK-pIgR-shRNA3 cells) at 2 × 10
6 cells resuspended in 100 µL 
phosphate-buffered saline (PBS) were injected into the lateral tail 
veins of SCID mice (n = 5 mice per group). SMMC-7721-mock or 
SMMC-7721-pIgR cells (1 × 10
6 cells per mouse, resuspended in 
100 µL PBS, n = 12 mice per group) were injected into the lateral 
tail veins of SCID mice. Sample size was calculated on the basis of 
80% power. The number of mice per group was greater than the 
minimum numbers required as determined by a power test on the 
basis  of  preliminary  studies—at  least  two  mice  per  group  were 
required for experiments with pIgR-overexpressing MDCK and 
control  cells,  whereas  three  mice  per  group  were  required  for   
experiments with pIgR-overexpressing SMMC-7721 and control 
cells. In preliminary experiments, we observed a 60% change of 
death  among  mice  injected  with  pIgR-overexpressing  SMMC-
7721 cells (data not shown); therefore, at least eight mice were 
needed to achieve 80% power. Survival was recorded daily. After 
10 weeks, the mice were killed by CO2, their lungs were removed, 
and  the  number  of  metastasis  nodules  on  the  lung  surface  was 
counted by the naked eye. Metastatic lungs were fixed with para-
formaldehyde (4%) before dehydration and paraffin embedding. 
Paraffin sections were stained with hematoxylin and eosin according 
to standard protocols or were subjected to IHC staining using a 
horseradish peroxidase–labeled streptavidin–biotin ABC kit (ZSGB-
BIO, Beijing, China) with hematoxylin as the counterstain.
Migration, Invasion, and Adhesion Assays
For  wound-healing  migration  experiments,  pIgR-overexpressing 
MDCK cell sets (MDCK-mock, MDCK-pIgR, MDCK-pIgR-con.
shRNA,  MDCK-pIgR-shRNA1,  MDCK-pIgR-shRNA2,  or 
MDCK-pIgR-shRNA3 cells) and pIgR-overexpressing SMMC-7721 
cell  sets  (SMMC-7721-mock  or  SMMC-7721-pIgR  cells)  were 
grown to form a monolayer with 90% confluency. Cells were then 
scraped with a p200 tip (Axygen Scientific, Union City, CA), and 
medium was replaced with fresh RPMI-1640 medium supplemented 
with  2%  FBS  or  DMEM  medium  supplemented  with  2%  FBS. 
Wound closure of the monolayered cells was monitored at the time of 
wounding (0 hour), and after 3, 6, and 9 hours with microphotographs 
at ×10 magnification using a Olympus IX51 research microscope with 
a DP-70 camera (both from Olympus, Tokyo, Japan). The experi-
ment was performed three independent times in triplicate.
For the transwell assay, MDCK (1× 10
5 cells) and SMMC-7721 
cells (2× 10
5 cells) were starved in serum- and growth factor-free 
medium for 12 hours and added to the top chambers of 24-well 
Transwell plates (8 µm; Corning Costar Corp, Corning, NY). The 
bottom chambers were filled with growth medium supplemented 
with 100 ng/mL secretory component (R&D Systems, Minneapolis, 
MN). Cultures were maintained for 48 hours, followed by removal 
of non-motile cells at the top of the filter with a cotton swab. 
Migrating cells were fixed in paraformaldehyde (4%) and stained 
with crystal violet (0.1%) for 15 minutes at room temperature. Dye 
that was taken up by cells bound to the membrane was released   
by addition of 100 µL 10% acetic acid, and the absorbance of   
the resulting solution was measured at 595 nm using a multiwell 
spectrophotometer (VERSAmax; Molecular Devices, Sunnyvale, 
CA). The assay was performed in triplicate and repeated twice.
For  the  matrigel  invasion  assay,  pre-starved  MDCK-mock, 
MDCK-pIgR, MDCK-pIgR-con.shRNA, MDCK-pIgR-shRNA1, 
MDCK-pIgR-shRNA2, or MDCK-pIgR-shRNA3 cells (5 × 10
4 cells 
per well) were cultured in the top chambers containing matrigel-
coated membrane inserts. The bottom chambers were filled with 
RPMI-1640 medium supplemented with 10% FBS. After incuba-
tion for a further 48 hours, cells were fixed in paraformaldehyde 
(4%) and stained with crystal violet (0.1%) for 15 minutes at room 
temperature, and images at ×10 magnification were taken using the 
Olympus  IX51  research  microscope  with  a  DP-70  camera.  The 
assay was performed three independent times in triplicate.
For the adhesion assay, MDCK-mock, MDCK-pIgR, MDCK-
pIgR-con.shRNA, MDCK-pIgR-shRNA1, MDCK-pIgR-shRNA2,   
or  MDCK-pIgR-shRNA3  cells  (3  ×  10
4  cells  per  well)  were 
cultured in fibronectin-coated 96-well plates in triplicate for 1 hour 
at 37°C. After gentle washing with PBS, non-adherent cells were 
discarded, and adherent cells were fixed with 5% glutaraldehyde 
and stained with 0.1% crystal violet. Dye that was taken up by cells 
bound to the membrane was dissolved in 100 µL 10% acetic acid, 
and the absorbance was measured at 595 nm using a multiwell 
spectrophotometer (VERSAmax; Molecular Devices). The experi-
ment was performed three independent times.
Urokinase-Type Plasminogen Activator (uPA)-Plasmingen 
Assay
MDCK (1.5 × 10
3 cells per well) and SMMC-7721 (6 × 10
3 cells per 
well) cells stably overexpressing an empty vector or pIgR cDNA 
were seeded in 96-well plates and grown overnight at 37°C. Then 
cells were cultured in fresh medium for 24 hours. Alternatively, 
HT29 cells were seeded at 6000 cells per well in 96-well plates and 
grown overnight at 37°C. Fresh medium containing tumor necro-
sis factor a (TNF-a) (5, 10, 20 ng/mL) (Peprotech Inc, Rocky 
Hill, NJ) was added to the appropriate wells and incubated for   
24 hours at 37°C. The plates were processed for determination of 
plasminogen activity by first rinsing twice with phenol red–free 
DMEM and then adding 200 µL of reaction buffer containing 
50% (vol/vol) 0.05 units/mL plasminogen (Roche) in phenol red–
free DMEM, 40% (vol/vol) 50 mM Tris–HCl pH 8.2, 10% (vol/vol) 
3 mM Chromozyme PL (Roche), and 0.2% tween 20 in 100 mM 
glycine  solution  to  each  well.  The  plates  were  incubated  for   
6 hours at 37°C, 5% CO2, and the absorbance of each well was 
read  using  an  automated  spectrophotometric  plate  reader 
(VERSAmax;  Molecular  Devices)  at  405  nm.  The  results  were   
repeated in three independent experiments.
Immunocytochemistry
pIgR-overexpressing MDCK cell sets (MDCK-mock, MDCK-pIgR,   
MDCK-pIgR-con.shRNA,  MDCK-pIgR-shRNA1,  MDCK- 
pIgR-shRNA2,  or  MDCK-pIgR-shRNA3  cells)  or  pIgR- 
overexpressing  SMMC-7721  cell  sets  (SMMC-7721-mock  or 
SMMC-7721-pIgR cells) were plated onto 24-well glass chamber 
slides (20 000 or 10 000 cells per well) and incubated at 37°C in a 
humidified incubator with 5% CO2 for 36 hours. The cells were 
fixed with 4% formaldehyde at room temperature for 1 hour and 
permeabilized with 0.1% Triton X-100 in PBS at room temperature 
for 5 minutes. Subsequently, cells were washed three times for   
5 minutes each using PBS containing 1% bovine serum albumin. Cells 
were incubated with primary antibodies (mouse anti-human E-cadherin 
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antibody [dilution, 1:100], mouse anti-human vimentin antibody 
[dilution, 1:100], or mouse anti-human fibronectin antibody [dilution, 
1:100]).  For  dual  immunostaining,  the  primary  antibodies  were 
goat  anti-human  pIgR  (C20)  antibody  (dilution,  1:100),  rabbit 
anti-human Smad2 antibody (dilution, 1:1000), rabbit anti-human 
Smad3 antibody (dilution, 1:1000), and mouse anti-human EEA1 
antibody (dilution, 1:100). The cells were washed three times for   
5 minutes each using PBS containing 1% bovine serum albumin 
and then incubated with Alexa Fluor 546 goat anti-mouse IgG 
(dilution,  1:1000)  or  Alexa  Fluor  488  rabbit  anti-mouse  IgG 
(dilution,  1:1000)  for  single  immunofluorescence  staining  and 
with Alexa Fluor 546 goat anti-mouse IgG (dilution, 1:1000) and 
Alexa Flour 488 rabbit anti-goat IgG (1:1000 dilution), or Alexa 
Fluor 546 goat anti-mouse IgG (dilution, 1:1000) and Alexa Flour 
488 goat anti-rabbit IgG (1:1000 dilution) for dual immunofluores-
cence staining at room temperature for 1 hour. Cells were observed 
using  a  Zeiss  LS510  confocal  microscope  (Carl  Zeiss,  Jena, 
Germany)  at  ×400  magnification  for  single  immunofluorescence 
experiments and an Olympus FV 1000 confocal microscope at ×600 
magnification for dual immunofluorescence experiments. All exper-
iments were repeated three independent times.
Statistical Analysis
All  data  (except  tissue  microarray  and  animal  survival  analyses) 
were  analyzed  using  Student  t  test.  Statistical  analysis  of  tissue 
microarrays was performed using the statistical package SPSS 
(version 16.0; SPSS Inc, Chicago, IL). DFS and Overall survival 
were assessed using the Kaplan–Meier method and compared with 
the log-rank test. Fisher exact test was applied to determine clini-
copathologic correlations. Univariable and multivariable risk ratios 
were computed with 95% confidence intervals (CIs). Univariable 
risk ratios with 95% confidence intervals were calculated using 
Cox proportional hazards regression models with forward stepwise 
selection (forward likelihood ratio). Models were adjusted by serum 
gamma glutamyl transferase (>54 or ≤54 U/L), a-fetoprotein (>20 
or ≤20 U/L), tumor encapsulation (none or complete), tumor size 
(>5 or ≤5 cm), the number of tumors (multiple or single), vascular 
invasion (yes or no), TNM stage (stage I or stages II–III), Barcelona 
Clinic Liver Cancer group stage (stages 0–A or stages B–D), pIgR 
(low or high expression, on the basis of a score ranging from 0 to 
4 [low] and 6 to 8 [high]). Multivariable risk ratios with 95% con-
fidence intervals were calculated using Cox multivariable analysis 
and Cox proportional hazards regression models. Covariables were 
adopted for their prognostic significance by univariate analysis (P < 
.05) with forward stepwise selection (forward likelihood ratio). Mouse 
survival analysis was analyzed using the Kaplan–Meier method and 
compared using the log-rank test. All statistical tests were two-sided, 
and P values less than .05 were considered statistically significant.
Results
pIgR  Expression  in  HCC  Patients  With  Early  Tumor 
Recurrence
We analyzed 254 tumor specimens from HCC patients for whom 
follow-up data was available after they underwent curative hepa-
tectomy. Of these HCC patients, 211 (83.1%) tested positive for 
hepatitis B surface antigen (HBsAg), an indicator of HBV infection 
(Supplementary Table 1, available online). The tumor specimens 
were grouped according to high- and low-levels of pIgR expres-
sion, and 98 specimens (38.6%) belonged to the high-expression 
group. Patients with high pIgR expression had a statistically signif-
icantly higher risk of early tumor recurrence as indicated by the 
decreased DFS compared with HCC patients with low levels of 
pIgR expression (log-rank P = .02, Figure 1, A; hazard ratio = 1.64, 
95% CI = 1.08 to 2.48, likelihood ratio test P = .02, Supplementary 
Table 2, available online, respectively). When stratified by sex, we 
found that high-level expression of pIgR was statistically signifi-
cantly associated with a higher risk of early recurrence, shown as 
decreased DFS in male HCC patients, as compared with female 
HCC  patients  (log-rank  P  =  .03  vs  .57,  respectively)  (data  not 
shown). Multivariable analyses adjusting for the clinicopathologic 
variables were adopted for their prognostic significance (P < .05) 
by univariate analyses, which further confirmed that high expression 
of pIgR was an independent prognostic predictor of early tumor 
recurrence in HCC patients (hazard ratio = 1.61, 95% CI = 1.07 to 
2.45, P = .02) (Table 1).
HBV-related carcinogenesis is a multistep process, encompassing 
the combination of different not mutually exclusive effects such as 
the induction of chronic liver inflammation and regeneration (37). 
HBsAg positivity indicates a clear HBV infection and harbors a 
higher risk to develop HCC, whereas the positivity of hepatitis B e 
antigen  (HBeAg)  usually  indicates  active  HBV  replication  (38). 
When  stratified  by  HBV  viral  status,  we  found  that  high-level   
expression of pIgR was statistically significantly associated with a 
higher  risk  of  early  recurrence,  shown  as  decreased  DFS  in 
HBsAg-positive HCC patients, as compared with HBsAg-negative 
patients (log-rank P = .02 vs .62, respectively) (Figure 1, B). A sim-
ilar  but  non-statistically  significant  trend  was  also  observed  in 
HBeAg-positive  patients  (HBeAg-positive  vs  HBeAg-negative 
HCC patients, log-rank P = .05 vs .14) (Supplementary Figure 1, 
A, available online). These findings suggest that HBsAg-associated 
chronically active inflammation may lead to increased pIgR protein 
expression that subsequently promotes tumor early recurrence.
Because loss of E-cadherin expression, a hallmark of EMT, is 
noted  in  many  malignancies  and  is  associated  with  metastatic 
potential (39–41), we examined E-cadherin levels using IHC staining 
and analyzed the relationship between E-cadherin and pIgR ex-
pression. High-level pIgR expression was statistically significantly 
associated (P = .02) with loss of E-cadherin (69.8%) (pIgR high 
expression  level  patients  vs  pIgR  low  expression  level  patients, 
E-cadherin  weak  positive  rate  =  69.8%  vs  45.7%,  difference  = 
24.1%, 95% CI of the difference = 4.2% to 44.0%) (Figure 1, C) 
in HCC specimens showing early tumor recurrence. Figure 1, D 
shows  the  corresponding  representative  IHC-stained  tissue  sec-
tions. This inverse association between pIgR and E-cadherin ex-
pression was also confirmed by immunoblotting (Supplementary 
Figure 1, B, available online). In addition, high-level expression of 
pIgR was also associated with reduced expression of another epithe-
lial marker, pan-cytokeratin, and with an elevated level of the mesen-
chymal  marker,  vimentin  (Supplementary  Figure  1,  B,  available 
online). Such a specific expression pattern suggests a role for pIgR 
in EMT induction in HCC patients.
High  expression  of  pIgR  remained  statistically  significantly   
associated with DFS and its reflecting early tumor recurrence in 1702   Articles | JNCI  Vol. 103, Issue 22  |  November 16, 2011
this scenario in patients with early stages of HCC when further 
stratified by the level of vascular invasion (P = .03), the number of 
tumors (P = .004), tumor size (P = .03), and TNM stage (P = .005) 
(Figure 2, A–D, left panel). In contrast, pIgR expression was not 
statistically significantly associated with DFS in patients with late-
stage HCC when stratified using these same variables (Figure 2, A–D, 
right panel). Because early recurrence is most likely the conse-
quence of occult metastasis from the initial tumor (31,33), our data 
suggest that high-level pIgR expression is closely associated with a 
higher risk of metastasis, particularly in patients at early stages of 
HCC. These results further suggest that pIgR may serve as an 
important tumor metastatic factor predicting metastatic potential 
in the clinic, particularly in the early stages of HCC.
Relationship Between pIgR Expression and EMT Induction 
In Vitro
To confirm the role of pIgR in EMT, we used a model epithelial 
cell line, MDCK, to generate six stable cell lines, one overexpressing 
pIgR (MDCK-pIgR) and the other five with pIgR shRNA knock-
down (MDCK-pIgR-shRNA1, shRNA2, shRNA3) and controls 
(MDCK-pIgR-con.shRNA and MDCK-mock). Parental MDCK 
cells exhibit a cobblestone morphology in monolayer cultures with 
tight cell–cell contacts, characteristic of epithelial cells. However, 
MDCK cells with elevated expression of pIgR showed loss of cell–
cell contact and displayed a spindle-like fibroblastic morphology, 
one of the principal characteristics of EMT (Figure 3, A). Such 
morphological changes were accompanied by almost complete loss of 
the epithelial markers E-cadherin and pan-cytokeratin (Figure 3, B, 
and Supplementary Figure 2, A, available online) and by increased 
expression of the mesenchymal markers vimentin and fibronectin 
(Figure 3, B, and Supplementary Figure 2, A, available online). 
The mesenchymal phenotype, including cellular morphology and 
the expression pattern of mesenchymal markers, displayed by the 
pIgR high-expressing MDCK cells was almost completely reversed 
by shRNA knockdown of pIgR (Figure 3, A–B, and Supplementary 
Figure 2, A, available online), indicating that pIgR is required for 
Figure 1. Association between polymeric immunoglobulin receptor 
(pIgR) expression and poor prognosis and relationship between pIgR 
and E-cadherin expression level in hepatocellular carcinoma (HCC) 
patients  after  resection.  A)  Comparison  of  disease-free  survival 
(DFS) (indicating early tumor recurrence, recurrence ≤2 years after 
resection) in HCC patients with high and low expression levels of 
pIgR.  Kaplan–Meier  survival  analysis  was  performed,  and  P  was 
calculated using a two-sided log-rank test. DFS rates with 95% confi-
dence intervals (light color lines) in patients with pIgR high or low 
expression  are  shown.  The  absolute  number  of  patients  at  risk  is 
listed below the curve. B) Kaplan–Meier survival analysis of hepatitis 
B  surface  antigen  (HBsAg)–positive  and  HBsAg-negative  HCC 
patients  by  pIgR  expression  (high  or  low)  was  performed,  and   
P values were calculated using a two-sided log-rank test. DFS rates 
with 95% confidence intervals (light color lines) in patients with pIgR 
high or low expression are shown. The absolute number of patients 
at risk is listed below the curve. C) E-cadherin expression patterns 
(weak or strong positive staining) were analyzed in HCC patients with 
high (n = 43) vs low (n = 46) pIgR who had early recurrence using the 
two-sided Fisher exact test. D) Representative immunostained images 
of pIgR and E-cadherin protein expression in HCC tissues (scale bars 
= 50 µm).jnci.oxfordjournals.org    JNCI | Articles 1703
induction of EMT in MDCK cells. Furthermore, high expression 
of pIgR was also sufficient to induce EMT in two hepatic carci-
noma cell lines: SMMC-7721 (Figure 3, A–B) and BEL-7404 (data 
not  shown),  as  well  as  a  normal  liver  cell  line  LO2  (data  not 
shown), when these cell lines were induced to transiently or stably 
overexpress pIgR.
We next examined whether cell motility was affected by pIgR-
induced EMT. Overexpression of pIgR resulted in a clear and 
potent migratory phenotype as assessed by a wound-healing assay 
in both SMMC-7721 (pIgR vs mock, mean migration distance at 
6 hours = 56.9 vs 15.5 µm; mean difference = 41.4 µm, 95% CI of 
the difference = 11.0 to 71.8 µm, P = .004; similar results were 
observed at 3 and 9 hours) (Figure 3, C) and MDCK cells (pIgR 
vs mock, mean migration distance at 6 hours = 81.5 vs 30.9 µm, 
mean difference = 50.6 µm, 95% CI of the difference = 35.7 to 
65.5 µm, P < .001; similar results were observed at 3 and 9 hours) 
(Figure  3,  D).  Matrigel  invasion  studies  also  revealed  that 
MDCK-pIgR  cells  were  statistically  significantly  more  invasive 
compared with MDCK-mock cells (Supplementary Figure 2, B, 
available online). Furthermore, high-level expression of pIgR was 
associated with a statistically significant decrease in cell adhesion 
(Supplementary Figure 2, C, available online). In agreement with 
these findings, overexpression of pIgR in MDCK and SMMC-
7721  cells  dramatically  activated  uPA  activity  (Figure  3,  E),  a 
hallmark of cancer cell invasion and metastasis (42,43). Conversely, 
pIgR knockdown in pIgR-overexpressing MDCK cells reversed 
the migratory phenotypes, as shown in the wound-healing assay 
(pIgR shRNA1 vs pIgR con.shRNA, mean migration distance at   
6 hours = 70.8 vs 80.1 µm, mean difference = 29.3 µm, 95% CI 
of the difference = 214.5 to 24.1 µm, P = .14; pIgR shRNA2 vs 
pIgR con.shRNA, mean migration distance at 6 hours = 48.0 vs 
80.1 µm, mean difference = 232.1 µm, 95% CI of the difference = 
264.0 to 20.2 µm, P = .004; pIgR shRNA3 vs pIgR con.shRNA, 
mean migration distance at 6 hours = 38.3 vs 80.1 µm, mean 
difference = 241.8 µm, 95% CI of the difference = 246.6 to 
237.0 µm, P = .001; similar results were observed at 3 and 9 hours) 
(Figure 3, D). Similar results were observed in matrigel invasion 
assay and adhesion assay (Supplementary Figure 2, B–C, available 
online).
Effect of Proinflammatory Cytokines on pIgR Expression 
and Its Association with EMT
Expression of pIgR is commonly increased by proinflammatory 
cytokines, including TNF-a, interferon g (IFN-g), and interleukin 
Figure  2.  The  prognostic  significance  of  polymeric  immunoglobulin 
receptor (pIgR) expression stratified by hepatocellular carcinoma stage. 
Kaplan–Meier survival analysis of early- and late-stage patients with 
high or low pIgR expression stratified by A) vascular invasion (present or 
not present), B) tumor number (1 or >1 tumor), C) tumor size (≤5 or >5 cm), 
and D) TNM stage (stage I or II–III). Disease-free survival rates with 95% 
confidence intervals (light color lines) in patients with pIgR high or low 
expression are shown. The absolute number of patients at risk is listed 
below each curve. P values were calculated using a two-sided log-rank 
test.
Table 1. Multivariable analyses of factors associated with DFS in 
254 hepatocellular carcinoma patients*
Variables†
DFS‡
HR (95% CI) P§
Tumor number (multiple vs single) 1.76 (1.07 to 2.92) .03
Vascular invasion (yes vs no) 2.28 (1.49 to 3.48) <.001
pIgR (high vs low) 1.61 (1.07 to 2.45) .02
*  CI = confidence interval; DFS = disease-free survival; HR = hazard ratio;  
pIgR = polymeric immunoglobulin receptor.
†  Cox multivariable analysis and Cox proportional hazards regression models 
were used. Variables were adopted for their prognostic significance by  
univariable analysis (P < .05) with forward stepwise selection (forward 
likelihood ratio).
‡  For patients who had a confirmed tumor recurrence, DFS was calculated as 
the time that early recurrence (≤2 years) was first suspected. DFS was used 
as surrogate endpoint for indicating early recurrence.
§  P values were calculated using a two-sided likelihood ratio test.1704   Articles | JNCI  Vol. 103, Issue 22  |  November 16, 2011
4 (IL-4), in response to viral or bacterial infections (16,17,19,44). 
Having established that high expression of pIgR was associated 
with early recurrence of chronically HBV-infected HCC patients, 
and  increased  pIgR  expression  induced  EMT,  we  next  asked 
whether elevated pIgR expression by the stimulation of proinflam-
matory cytokines could induce EMT induction in vitro. To this 
end, we chose a model cell line, human colonic adenocarcinoma 
HT29, which can respond well to the stimulation of cytokines in 
terms  of  increasing  pIgR  expression  (16,17).  We  exposed  the 
HT29 cell line to various concentrations of proinflammatory cyto-
kines and, as expected, exposure to high concentrations of TNF-a, 
IL-4, or IFN-g increased expression of pIgR and vimentin and 
Figure 3. Effect of polymeric immunoglobulin receptor (pIgR) expres-
sion on induction of epithelial–mesenchymal transition. A) Morphology 
of Madin–Darby canine kidney (MDCK) (top panel) and SMMC-7721 
(bottom panel) cells stably expressing pIgR cDNA alone or pIgR short 
hairpin  RNA  (shRNA)  plus  pIgR  cDNA  (scale  bar  =  50  µm).  B) 
Immunoblot  analysis  of  MDCK  cells  stably  expressing  pIgR  (top 
panel)  and  SMMC-7721  cells  transiently  expressing  pIgR  (bottom 
panel). Experiments were repeated three times with similar results. 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a 
loading control. C) The migration distance of SMMC-7721 cells stably 
expressing  pIgR  cDNA  alone  or  pIgR  cDNA  plus  pIgR  shRNA  was   
analyzed using a wound-healing assay. Data from three independent 
experiments performed in triplicate are presented as the mean with 
the SD (error bars). * P = .001, † P = .004, ‡ P < .001, vs the mock-
transfected (control) cells. D) The migration distance of MDCK cells 
stably expressing pIgR cDNA alone or pIgR cDNA plus pIgR shRNA 
was analyzed using a wound-healing assay. Data from three indepen-
dent experiments performed in triplicate are presented as the mean 
with  the  SD  (error  bars).  All  P  values  were  calculated  using  the 
two-sided Student t test. E) Urokinase-type plasminogen activator (uPA) 
activation  in  MDCK  and  SMMC-7721  cells  stably  expressing  pIgR 
cDNA  was  investigated.  Data  from  three  independent  experiments 
performed in triplicate are presented as the mean with the SD (error 
bars).  *  P  <  .001,  vs  mock.  All  P  values  were  calculated  using  the 
two-sided Student t test. OD = optical density.jnci.oxfordjournals.org    JNCI | Articles 1705
decreased expression of E-cadherin in a dose-dependent and time-
dependent  manner  (Figure  4,  A–C).  Moreover,  knockdown  of 
pIgR in TNF-a-treated HT29 cells triggered a decrease in vimentin 
and an increase in E-cadherin (Figure 4, D). Together, these data 
indicate that proinflammatory cytokines induce expression of pIgR, 
which  in  turn  activates  EMT,  a  critical  step  for  inflammation- 
initiated tumor progression. In TNF-a-stimulated HT29 cells, a 
statistically significant increase in pIgR expression was also accom-
panied by increased uPA activity (Figure 4, E), further supporting 
the role of pIgR in EMT induction.
Effect of pIgR Overexpression on Metastatic Lesions In 
Vivo
To determine the in vivo consequences of pIgR overexpression, we 
injected MDCK-mock, MDCK-pIgR, MDCK-pIgR-con.shRNA, 
or MDCK-pIgR-shRNA3 cells into the lateral tail veins of SCID 
mice (n = 5) and evaluated the survival of cells in circulation and 
their metastatic growth in the lung. After 10 weeks, the MDCK-
pIgR-injected  mice  displayed  a  statistically  significantly  higher 
number of lung metastases than mice injected with MDCK-mock 
cells (pIgR mean = 29.4 metastatic nodules per lung vs control 
mean = 0.0 metastatic nodules per lung, difference = 29.4 meta-
static nodules per lung, 95% confidence interval = 13.0 to 45.8,   
P = .001), indicative of extravasation to and tumor growth in the 
lung (Figure 5, A and B). When lungs underwent hematoxylin and 
eosin staining, lung metastases were observed in all five mice intra-
venously  injected  MDCK-pIgR  cells,  whereas  no  obvious  lung 
metastases  were  observed  in  the  mice  intravenously  injected 
MDCK-mock cells (Figure 5, C shows representative hematoxylin- 
and eosin-stained lung sections). In contrast, MDCK-pIgR-shRNA3 
Figure  4.  The  effect  of  polymeric  immunoglobulin 
receptor (pIgR) up-regulation by proinflammatory cy-
tokines on induction of epithelial–mesenchymal tran-
sition  in  HT29  cells.  HT29  cells  treated  with  the 
indicated concentrations of A) TNF-a, B) IL-4, or C) 
IFN-g  in  serum-free  medium  for  48  hours  (left 
panels)  or  after  treatment  in  serum-free  medium 
for 0, 12, 24, 48, and 72 hours (right panels) under-
went  immunoblot  for  pIgR,  E-cadherin,  and 
vimentin expression. Glyceraldehyde-3-phosphate 
dehydrogenase  (GAPDH)  was  used  as  a  loading 
control. The experiment was repeated three times 
with  similar  results.  D)  pIgR  siRNA3-transfected 
HT-29 cells were treated with TNF-a in serum-free 
medium for 48 hours and analyzed by immunoblot-
ting  for  pIgR,  E-cadherin,  vimentin,  and  GAPDH 
(loading control). Data are representative of three 
independent experiments. E) urokinase-type plas-
minogen  activator  (uPA)  activation  in  HT29  cells 
treated with TNF-a for 48 hours was determined. 
Data  from  three  independent  experiments  per-
formed in triplicate are presented as the mean with 
SD (error bars). *P < .001 vs untreated HT29 cells, 
as  calculated  using  the  two-sided  Student  t  test. 
IFN-g = interferon g; IL-4 = interleukin 4; siRNA = 
short  interfering  RNA;  TNF-a  =  tumor  necrosis 
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cells  did  not  metastasize  or  had  statistically  significantly  fewer 
metastatic nodules per lung (pIgR shRNA3 vs pIgR con.shRNA, 
mean number of metastatic nodules per lung = 0.4 vs 22.2 nodules, 
mean difference = 221.8 nodules, 95% CI of the difference = 243.3 
to 20.3 nodules, P = .03) (Figure 5, A–C). Similar results were 
obtained in mice injected with liver cancer cells that have pIgR 
Figure 5. Effect of polymeric immunoglobulin receptor (pIgR) overex-
pression on metastasis in vivo. The metastatic abilities of Madin–Darby 
canine kidney (MDCK) cells stably expressing an empty vector (Mock), 
pIgR cDNA, pIgR cDNA plus control (non-targeting) short hairpin RNA 
(shRNA), or pIgR cDNA plus pIgR shRNA3 were examined in severe 
combined immunodeficient (SCID) mice via tail vein injection. A) The 
number  of  metastatic  nodules  on  the  surface  of  the  lungs  of  mice 
injected with the MDCK cells (n = 5 mice per group) was determined. 
Data are presented as the mean and SD (error bars). *P = .001 vs the 
mock group, and † P = .03 vs the pIgR con.shRNA group. All P values 
were calculated using the two-sided Student t test. This experiment was 
repeated three times with similar results. B) Representative images of 
lungs on day 70 after mice were injected with MDCK stable transfec-
tants (scale bar = 5 mm). C) Representative images of hematoxylin and 
eosin (H&E) and immunohistochemical staining of pIgR in lung tissues 
of mice injected with MDCK stable transfectants (scale bar = 50 µm, at 
×40 magnification) are shown. D–F) The metastatic abilities of SMMC-
7721 cells stably expressing empty vector (mock) or pIgR cDNA were 
examined in SCID mice via tail vein injection. D) Number of metastatic 
nodules on the surface of the lungs of mice injected with SMMC-7721 
transfectants (n = 11 mice in the mock group and n = 5 mice in the pIgR 
group) are presented as the mean and SD (error bars). *P = .03 vs the 
mock group, calculated by the two-sided Student t test. E) Representative 
images of H&E stained of lung tissues from mice injected with SMMC-
7721 transfectants (scale bar = 50 µm). F) The comparison of survival 
curves of mice injected with either SMMC-7721-pIgR or SMMC-7721-
mock vectors. Survival rates with 95% confidence intervals (light color 
lines)  in  mice  injected  with  either  SMMC-7721-pIgR  or  SMMC-7721-
mock vectors are shown. P was calculated by the two-sided log-rank 
test. The absolute number of mice at risk is listed below the curve. 
The last column number indicates the number of mice at risk on day 69. 
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overexpression (SMMC-7721-pIgR cells: pIgR mean = 10.4 meta-
static nodules per lung vs control mean = 2.2 metastatic nodules 
per lung, difference = 8.2 metastatic nodules per lung, 95% confi-
dence interval = 1.0 to 15.5, P = .03) (Figure 5, D–E). These mice 
had a statistically significantly shorter survival rate (survival rate 
analysis  of  mice  intravenously  injected  pIgR-overexpressing 
SMMC-7721 cells, pIgR vs mock, survival rate = 41.7% vs 91.7%, 
difference  =  250%,  95%  CI  of  the  difference  =  282.0%  to 
218.0%, P = .007) compared with mice that were injected with 
SMMC-7721  cells  with  barely  detectable  expression  of  pIgR 
(Figure 5, F). Our data thus indicate that pIgR is necessary for the 
development of the aggressive and highly metastatic phenotype.
Relationship Between pIgR Overexpression and Activation 
of Smad Signaling
To determine the molecular basis of how pIgR induces EMT, we 
focused on the Smad signaling pathway that is known to play a major 
role in EMT induction. Increased expression of pIgR in MDCK and 
SMMC-7721 cells caused a dramatic activation of Smad2/3 com-
pared  with  the  mock  control–treated  cells  (Figure  6,  A).  Similar 
results were obtained for TNF-a-, IL-4-, and IFN-g-treated HT29 
cells (Supplementary Figure 3, A–C, available online). To further 
confirm the ability of pIgR to induce Smad activation, we used shR-
NAs or siRNA to knock down pIgR expression. Knockdown of pIgR 
resulted in a substantial decrease in phosphorylated Smad 2/3 in 
pIgR-overexpressing MDCK cells (Figure 6, A) and in TNF-a-treated 
HT29 cells (Supplementary Figure 3, D, available online), suggesting 
that pIgR was required for Smad activation. Because transforming 
growth factor b (TGF-b), a known Smad canonical stimuli, syner-
gizes with proinflammatory cytokines in EMT induction (14,45–48), 
we introduced TGF-b to MDCK-pIgR, SMMC-7721-pIgR, and 
TNF-a-stimulated HT29 cells. We found that TGF-b caused a 
dramatic increase in Smad2/3 phosphorylation and vimentin expres-
sion and a decreased in E-cadherin expression, when compared with 
the  TGF-b-untreated  pIgR  high-expressing  cells  at  both  24  and 
48  hours  (Figure  6,  B  and  Supplementary  Figure  3,  E,  available 
online). These data indicated that TGF-b and pIgR converged in 
activating Smad2/3 as part of EMT induction.
We next determined whether pIgR-induced EMT was medi-
ated by Smad activation. Transfection of MDCK-pIgR or SMMC-
7721-pIgR cells with either Smad2/3 or Smad2 siRNAs almost 
completely  reversed  the  pIgR-driven  EMT  as  measured  by  an 
increase in E-cadherin and cytokeratin and a decrease in vimentin 
levels (Figure 6, C). Smad3 siRNAs also inhibited pIgR-directed 
EMT but to a lesser extent compared with Smad2 knockdown. 
These data indicate that activation of Smads, particularly Smad2, 
is essential for pIgR-induced EMT.
To determine whether pIgR promotes Smad activation in vivo, 
we examined Smad2/3 phosphorylation in HCC samples. Increased 
levels of phospho-Smad2/3 were observed in pIgR-overexpressing 
HCC samples that exhibited EMT characteristics (Supplementary 
Figure 1, B, available online), indicating that high levels of pIgR 
expression lead to increased Smad activation and EMT induction.
Mechanism of Smad Activation by pIgR
To determine how pIgR activates Smad, we tested whether pIgR 
plays a direct role in recruiting the Smad signaling complex. Using 
immunofluorescence  assay  in  pIgR-expressing  MDCK  and 
SMMC-7721 cells, we found that overexpression of pIgR increased 
Smad2/3 nuclear translocation (Supplementary Figure 4, A and B, 
available online). More importantly, we found that pIgR, Smad2, 
and Smad3 were colocalized extensively with EEA1, an early endo-
some marker (Supplementary Figure 4, A and B, available online). 
Specifically, pIgR and Smad2/3 were present in the same endocytic 
compartment, the EEA1-positive early endosome. This finding is 
consistent with a previous report that both pIgR and Smad2/3 are 
localized  to  EEA1-positive  early  endosomes  (18,49–52). 
Furthermore, endogenous Smad2/3 was immunoprecipitated with 
an anti-pIgR antibody from cell lysates from MDCK-pIgR cells 
and pIgR transiently expressing SMMC-7721 cells, and vice versa 
(Figure  6,  D).  These  reciprocal  co-immunoprecipitation  data 
suggest  that  pIgR  activates  Smad  signaling  by  recruiting  the 
Smad2/3  complex.  To  identify  which  component  is  the  direct   
target  of  pIgR,  we  repeated  the  co-immunoprecipitation  with   
lysates from MDCK-pIgR cells and pIgR transiently overexpressing 
SMMC-7721  cells  after  treatment  with  siRNA  for  Smad2  or 
Smad3. Knockdown of Smad2, but not Smad3, led to disruption of 
pIgR-Smad interactions, suggesting that pIgR plays a direct role in 
recruiting Smad2 (Figure 6, E). We also found that endogenous 
pIgR interacted with endogenous Smad2/3 in HT29 cells after 
exposure to IL-4 (Supplementary Figure 3, F, available online). 
Together, our data suggest that pIgR is a novel partner of the 
Smad complex and that it activates Smad signaling by recruiting 
Smad2.
We also found that expression of pIgR increased the protein 
levels of Snail, Slug, and ZEB1, but not Twist1/2, which are all 
key E-cadherin repressors required for EMT (40,47). Knockdown 
of pIgR in MDCK pIgR-expressing cells resulted in a dramatic 
reversion in the expression pattern of these E-cadherin repressors 
(Supplementary Figure 5, A2B, available online). These data sug-
gest that pIgR-mediated Smad activation converges on the EMT 
signaling pathways regulated by the Snail, Slug, and ZEB1 tran-
scription factors.
The Role of Serines 682 and 734 in the Cytoplasmic Tail of 
pIgR in EMT Induction
Our results so far have established that pIgR has a signaling role in 
EMT induction in addition to its classic function as a transporter 
of dIgA and pIgM. To further map which residues in the cytoplasmic 
domain of pIgR are essential for signaling in EMT induction, we 
performed a series of point mutations in tyrosine residues 677 and 
743 and serine residues 673, 682, 734, and 735, because phosphor-
ylation of these residues is likely to play a signaling role in pIgR-
mediated EMT induction. Tyrosine 677 and 743 and serine 673 
and 735 are known to play critical roles in transcytosis, a key step 
in transportation of dIgA and pIgM by pIgR during the immune 
response  (18,53–55).  However,  mutations  of  Y677F,  Y743F, 
S673A, and S735A had little effect on the ability of pIgR to induce 
EMT  in  MDCK  and  SMMC-7721  cells  (Figure  7,  A  and 
Supplementary  Figure  6,  A,  available  online).  In  addition,  the 
cleaved  extracellular  domain  of  pIgR,  which  is  responsible  for 
binding to dIgA and pIgM, failed to induce EMT (Supplementary 
Figure 6, B–C, available online). Together, these data indicate that 
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Figure 6. Activation of Smad signaling by polymeric immunoglobulin 
receptor  (pIgR).  A)  Protein  lysates  from  Madin–Darby  canine  kidney 
(MDCK)  cells  stably  expressing  pIgR  cDNA  or  pIgR  cDNA  plus  pIgR 
short hairpin RNA (shRNA) (top panel) and SMMC-7721 cells transiently 
expressing pIgR cDNA (bottom panel) were immunoblotted for phos-
pho-Smad2  and  phospho-Smad3  (p-Smad2  and  p-Smad3,  respec-
tively).  Glyceraldehyde-3-phosphate  dehydrogenase  (GAPDH)  and 
b-actin served as a loading control. B) MDCK stable transfectants (top 
panel) and SMMC-7721 transient transfectants (bottom panel) under-
went immunoblotting for p-Smad2 and pSmad3 24 hours after treat-
ment  with  TGF-b  (5  ng/mL)  or  were  immunoblotted  for  E-cadherin, 
pan-cytokeratin, and vimentin 48 hours after transforming growth fac-
tor-b  (TGF-b)  treatment.  GAPDH  served  as  a  loading  control.  C) 
Immunoblots  of  epithelial  and  mesenchymal  markers  and  activated 
Smad2  and  Smad  3  in  MDCK  stable  transfectants  (top  panel)  and 
SMMC-7721  transient  transfectants  (bottom  panel)  after  a  separate 
transfection with Smad2 and Smad3 siRNAs. D) Co-immunoprecipitation 
of Smads and pIgR from whole-cell lysates (WCL) prepared from MDCK 
cells (top panel) and SMMC-7721 cells (bottom panel) as described in 
(A). Co-immunoprecipitation with IgG served as a negative control. 
E)  Anti-pIgR  immunoprecipitates  from  Smad2  or  Smad3  depleted–
MDCK cells stably expressing pIgR (left panel) and SMMC-7721 cells 
transiently expressing pIgR (right panel) were analyzed by immuno-
blotting for Smads and pIgR. All images are representative of data from 
three  independent  experiments.  IP  =  immunoprecipitation;  siRNA  = 
short interfering RNA.jnci.oxfordjournals.org    JNCI | Articles 1709
transportation differ from those required for pIgR-mediated EMT 
induction.
In contrast, mutations in serine residues 682 and 734 (S682A/
S734A and S734A) nearly abolished the ability of pIgR to induce 
EMT (Figure 7, A–B), suggesting that these residues are critical 
for pIgR-induced EMT. Given the essential role of Smad activation 
in pIgR-driven EMT, we tested whether S682 and S734 partici-
pated in pIgR-directed Smad activation. Whereas wild-type pIgR 
induced  Smad2/3  phosphorylation,  the  S682A/S734A  double 
mutant failed to induce Smad2/3 phosphorylation in MDCK or 
SMMC-7721 cells (Figure 7, B). Furthermore, the S682A/S734A 
double mutation substantially reduced interactions between pIgR 
and  Smad2/3  (Figure  7,  C).  These  findings  suggest  that  serine 
residues at positions 734 and 682 are not only required for pIgR 
binding to Smads but also for Smad activation that leads to EMT 
induction.
Discussion
In this study, we demonstrated that pIgR is a signaling mediator of 
HBV-related hepatitis and HCC metastasis. High expression of 
pIgR was inversely associated with DFS and was associated with 
poor  prognosis  in  HCC  patients.  Data  showed  that  the  pIgR   
expression  level  may  indicate  the  metastatic  potential  of  early-
stage HCC. Mechanistically, pIgR induced the EMT process in 
vitro  and  in  vivo  through  activation  of  Smad  signaling.  These 
results establish a missing link between hepatitis-related chronic 
inflammation, EMT, and HCC metastasis.
It is well known that inflammatory immune responses to HBV 
viral antigens induce hepatocyte damage, followed by the regener-
ation of hepatocytes and the development of fibrosis and cirrhosis, 
which are the important features in pathogenesis of HCC (37,56). 
In  fact,  HBsAg  positivity  indicates  a  clear  HBV  infection;  and 
HBeAg positivity usually reflects active replication with ongoing 
inflammation and progression of HCCs. In this study, we showed 
that  high-level  pIgR  in  HBsAg-positive  patients  was  associated 
with a higher risk of early recurrence in HCC patients, indicating 
that  the  chronic  HBV  viral  infection  in  hepatitis-related  HCC 
causes the changes of microenvironment such as the release of 
proinflammatory cytokines that increase pIgR expression to pro-
mote  HCC  metastasis.  Indeed,  we  also  observed  a  statistically 
significant  association  between  TNF-a  and  pIgR  expression  in 
HCC patients who had early recurrence, indicated by shorter DFS 
(data  not  shown).  Notably,  in  the  same  specimens  from  early-
recurrence HCC patients, increased pIgR levels are accompanied 
by a loss of E-cadherin, the hallmark of EMT, indicative of the 
clinical significance of pIgR in promoting tumor recurrence and 
metastasis  via  EMT  induction.  The  proinflammatory  cytokines 
TNF-a,  IL-4,  and  IFN-g  were  observed  to  increase  pIgR  and 
promote a clear EMT induction. Our data presented here show 
that pIgR is involved in EMT induction and may be a mechanistic 
link  between  hepatitis-related  chronic  inflammation  and  HCC 
Figure 7. Identification of the serine residue in 
the cytoplasmic tail of polymeric immunoglob-
ulin  receptor  (pIgR)  that  is  necessary  for  the   
induction of epithelial–mesenchymal transition. 
A)  Madin–Darby  canine  kidney  (MDCK)  (left 
panel) and SMMC-7721 (right panel) cells tran-
siently  transfected  with  empty  vector  (mock), 
wild-type pIgR, or the indicated pIgR mutants 
were  analyzed  using  immunoblotting  for  epi-
thelial  and  mesenchymal  markers.  B)  MDCK 
(left panel) and SMMC-7721 (right panel) cells 
transiently  transfected  with  an  empty  vector 
(mock)  or  indicated  pIgR  mutants  were  ana-
lyzed by immunoblot for activated Smad2 and 
Smad3,  and  E-cadherin,  pan-cytokeratin,  and 
vimentin.  C)  Anti-pIgR  immunoprecipitates 
from MDCK (left panel) and SMMC-7721 (right 
panel) cells transiently transfected with empty 
vector (mock), wild-type pIgR, or the indicated 
pIgR mutant were analyzed by immunoblot for 
Smad2,  Smad3,  and  pIgR.  Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) served as 
a  loading  control  for  all  experiments.  Similar 
results were seen in three independent experi-
ments. IP = immunoprecipitation; WCL = whole-
cell lysates.1710   Articles | JNCI  Vol. 103, Issue 22  |  November 16, 2011
metastasis, indicating that chronic inflammation to HCC is a deci-
sive factor in EMT induction in HCC metastasis (14,57).
The mainstream view of inflammation and cancer is currently 
focused on inflammatory cytokines such as TNF-a and their asso-
ciated  signaling  pathways.  Identification  of  pIgR  as  a  signaling 
mediator of inflammation-induced EMT provides a missing link 
between HBV-related chronic inflammation and HCC metastasis. 
To the best of our knowledge, pIgR is the first example of a well-
known immunoglobulin receptor involved in HBV-related hepati-
tis-mediated EMT and HCC metastasis. The discovery of this new 
role  could  provide  a  basis  for  the  study  of  novel  mechanisms   
underlying inflammation-mediated HCC progression.
The important mechanistic finding from our study is that pIgR-
induced EMT is mediated by the activation of Smad complex. pIgR 
activates Smad signaling by recruiting Smad2/3 complex, which is 
consistent with the fact that both pIgR and Smad2/3 are colocalized 
in EEA1-postive early endosomes, in which pIgR participates in 
transcytosis during the immune response (18,52) and Smad2/3 are 
activated for signal transduction (49–51). The ability of pIgR to 
activate  Smad  signaling  suggests  that  pIgR  functions  as  a  novel 
partner of the Smad2/3 signaling complex and establishes the first 
link between a known immunoglobulin receptor and the Smad sig-
naling pathway. Integrating all the results, we propose a signaling 
pathway from inflammation to EMT induction. In this pathway, 
inflammation induced by infections or tumor microenvironments 
leads to chronic production of cytokines such as TNF-a, which 
results in overexpression of pIgR and activation of Smad signaling 
that in turn leads to EMT induction and tumor metastasis.
Generally, the transport of dIgA and pIgM by pIgR is mediated 
by the ligand binding to the extracellular domain and by transcytosis 
that requires the cytoplasmic tail of pIgR (18,19). Our mutagenesis 
studies revealed that different structural elements are required for 
the transport function and for the EMT induction, respectively. 
Mutations  in  tyrosine  and  serine  residues  (Y677F  and  Y743F; 
S673A and S735A) that are important for transcytosis do not affect 
EMT  function  of  pIgR,  but  mutations  in  two  serine  residues 
(S682A and S734A) unrelated to transcytosis nearly abolish the 
ability of pIgR to induce EMT, suggesting that transcytosis and 
EMT induction of pIgR are mediated through two distinct sig-
naling pathways. The critical function of S682 and S734 in pIgR-
mediated EMT induction also suggests that phosphorylation of 
these residues may play an important role, and the exact signaling 
pathways leading to their phosphorylation warrant future investi-
gation.  The  new  role  of  pIgR  in  EMT  revealed  in  this  study 
suggests that pIgR has at least two functions: one as the transporter 
of  dIgA  and  pIgM  and  the  other  as  a  signaling  molecule  for 
inflammation-induced EMT.
Establishing the role of pIgR in EMT also helps to resolve the 
long-standing conflict on the clinical relevance of pIgR in tumor 
progression  (23,24,58–62).  This  is  a  reminiscent  of  the  debate 
about the significance of EMT in tumor progression and its rele-
vance in human cancers, which was not established until recently 
because EMT is transient and reversible (10,63,64). We observed 
a  statistically  significant  association  between  high  but  not  low   
expression of pIgR and the metastatic risk for early (but not late) 
stages  of  HCC,  suggesting  that  pIgR-driven  EMT  is  indeed  a 
transient event at the early stages of HCC. This observation is 
consistent with previous hypotheses that metastasis is not neces-
sarily a late event in tumor progression (10,65). The discrepancy 
regarding pIgR expression and clinical relevance in various tumors 
may be resolved if the stages of the tumors and the subtle charac-
teristics of EMT, which are easily overlooked in clinical samples, 
are taken into account.
Our study has a few limitations. Although we have noted a clear 
trend  that  high  expression  of  pIgR  is  associated  with  the  early   
recurrence in HBeAg-positive HCC patients, it was not statistically 
significant, most likely because of the limited number of patients 
enrolled in the study. An expanded patient cohort will probably 
validate  this  observation.  Moreover,  our  novel  findings  that 
increased  pIgR  expression  promotes  EMT  have  expanded  the   
understanding of the role of pIgR in cancer metastasis, but the 
detailed regulatory network is presumably far more expansive than 
what our study has shown. It, therefore, will be important to carry 
out further investigations to identify additional signaling modulators 
and delineating pivotal regulatory mechanisms involving pIgR and 
metastasis.
In  summary,  we  demonstrate  that  pIgR  is  a  novel  signaling 
mediator  of  HBV-related  chronic  inflammation–induced  tumor 
metastasis  via  EMT  induction  besides  its  normal  function  as  a 
transporter of IgA and IgM. Given a major obstacle for the poor 
prognosis of HCC is recurrence and metastasis after surgery or 
ablation  therapy  (4–7),  identification  of  pIgR  as  a  predictor  of 
metastatic potential in early-stage HCC patients could facilitate 
patient stratification and therapeutic decisions at early stage, there-
fore affecting the clinical outcome. Our study not only reveals a 
missing link between HBV-related chronic inflammation and HCCs 
metastasis but also provides a potential predictive biomarker for 
prognosis of HCC and a potential therapeutic target.
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